Honeybear Biosciences Achieves Another Milestone, Honored with the 24th “New Business Venture Award”
This November, Honeybear Biosciences once again drew everyone’s attention with its innovative antibody drug conjugate technology platform and R&D achievements. At the 24th “Business Startup Award,” organized by the Ministry of Economic Affairs, Honeybear Biosciences stood out among numerous submissions and was selected as one of the award-winning companies in the “Technology Industry” category. Vice Chairwoman Sarina Lin took the stage on behalf of the company to receive the award from Minister Ming-Hsin Kung, who highly affirmed the company’s progress.
During the event, an interesting byplay to be mentioned: when Sarina mentioned that Honeybear’s core technology was licensed from the Development Center for Biotechnology (DCB), Minister Kung expressed strong appreciation and noted that he had served as Chairman of DCB from 2017 to 2019, leading to a lively and engaging conversation between them.
CoNectar® Platform Technology and Corporate Governance: A Unique and Innovative Dual Strength
This award recognition comes from Honeybear’s proprietary CoNectar® technology platform, which has brought breakthroughs to the field of Antibody Radionuclide Conjugates (ARC). Unlike traditional high-dose radiotherapy, the CoNectar® platform can precisely deliver trace amounts of radionuclides to tumor cells with high specificity, allowing drug accumulation at the lesion site and, in theory, significantly reducing radiation damage to normal cells.
This technology not only offers improved safety but also high therapeutic potential, presenting new hope for patients suffering from the difficult-to-treat cancers.
Well structured Honeybear team brings together top talents from multiple disciplines, and its leadership collectively has over 200 years of combined industry experiences and know-how. Since its establishment in 2021, the company has secured exclusive technology licensing from DCB in 2022, collaborated with radiology experts at the University of California, San Francisco (UCSF), and completed two technology licensing and co-development agreements with A*STAR Singapore in 2025. No matter technological innovation or international collaboration, the company has built strong momentum.
Thanks to these strengths, Honeybear successfully passed the preliminary review and on-site evaluation, ultimately winning the favor of the judges and earning recognition in the “Technology Industry” category.
International Recognition and Commercial Expansion Advance in Parallel
In fact, Honeybear Biosciences had already demonstrated outstanding performance earlier this year. In March, based on the CoNectar® platform, the company received the “Best ADC Developer in Taiwan” award at the Asia Pacific Biopharma Excellence Awards 2025, organized by IMAPAC—marking its rising competitiveness on the global biotech stage.
Following this, Honeybear also shined at the NBRP Demo Day competition hosted by the National Biotechnology Research Park, winning the Second Place Overall with the “Potential Award.” With the latest recognition received on November 19—the “Business Startup Award”—the media has praised Honeybear Biosciences as a “consistent award-winning powerhouse.”
Meanwhile, the company is planning to submit its first Investigational New Drug (IND) application in 2026, officially entering the clinical development phase. CEO Simon, Shih-Hsien Chuang stated that the company will continue to advance technology and strengthen international partnerships following its dual ADC/ARC strategy, hoping to accelerate the transformation of CoNectar® platform breakthroughs into clinical therapies that benefit cancer patients.
Looking Forward: Technological Innovation to Drive Globalization of New Drugs
This award is a strong affirmation of Honeybear’s progress in R&D, technology development, corporate governance, and international collaboration. It also reflects the high expectations from the industry regarding the potential of the CoNectar®/ARC platform.
Chairman Edward Wang commented that Honeybear Biosciences will continue to uphold its corporate values of innovation, integrity, and responsibility, seize global trends and opportunities in the biotech industry, and strive to transform its research achievements into new drugs that genuinely improve human health.
Looking forward, Honeybear is confident in stepping onto the global stage and authoring a new chapter in cancer treatment.
This November, Honeybear Biosciences once again drew everyone’s attention with its innovative antibody drug conjugate technology platform and R&D achievements. At the 24th “Business Startup Award,” organized by the Ministry of Economic Affairs, Honeybear Biosciences stood out among numerous submissions and was selected as one of the award-winning companies in the “Technology Industry” category. Vice Chairwoman Sarina Lin took the stage on behalf of the company to receive the award from Minister Ming-Hsin Kung, who highly affirmed the company’s progress.
During the event, an interesting byplay to be mentioned: when Sarina mentioned that Honeybear’s core technology was licensed from the Development Center for Biotechnology (DCB), Minister Kung expressed strong appreciation and noted that he had served as Chairman of DCB from 2017 to 2019, leading to a lively and engaging conversation between them.
CoNectar® Platform Technology and Corporate Governance: A Unique and Innovative Dual Strength
This award recognition comes from Honeybear’s proprietary CoNectar® technology platform, which has brought breakthroughs to the field of Antibody Radionuclide Conjugates (ARC). Unlike traditional high-dose radiotherapy, the CoNectar® platform can precisely deliver trace amounts of radionuclides to tumor cells with high specificity, allowing drug accumulation at the lesion site and, in theory, significantly reducing radiation damage to normal cells.
This technology not only offers improved safety but also high therapeutic potential, presenting new hope for patients suffering from the difficult-to-treat cancers.
Well structured Honeybear team brings together top talents from multiple disciplines, and its leadership collectively has over 200 years of combined industry experiences and know-how. Since its establishment in 2021, the company has secured exclusive technology licensing from DCB in 2022, collaborated with radiology experts at the University of California, San Francisco (UCSF), and completed two technology licensing and co-development agreements with A*STAR Singapore in 2025. No matter technological innovation or international collaboration, the company has built strong momentum.
Thanks to these strengths, Honeybear successfully passed the preliminary review and on-site evaluation, ultimately winning the favor of the judges and earning recognition in the “Technology Industry” category.
International Recognition and Commercial Expansion Advance in Parallel
In fact, Honeybear Biosciences had already demonstrated outstanding performance earlier this year. In March, based on the CoNectar® platform, the company received the “Best ADC Developer in Taiwan” award at the Asia Pacific Biopharma Excellence Awards 2025, organized by IMAPAC—marking its rising competitiveness on the global biotech stage.
Following this, Honeybear also shined at the NBRP Demo Day competition hosted by the National Biotechnology Research Park, winning the Second Place Overall with the “Potential Award.” With the latest recognition received on November 19—the “Business Startup Award”—the media has praised Honeybear Biosciences as a “consistent award-winning powerhouse.”
Meanwhile, the company is planning to submit its first Investigational New Drug (IND) application in 2026, officially entering the clinical development phase. CEO Simon, Shih-Hsien Chuang stated that the company will continue to advance technology and strengthen international partnerships following its dual ADC/ARC strategy, hoping to accelerate the transformation of CoNectar® platform breakthroughs into clinical therapies that benefit cancer patients.
Looking Forward: Technological Innovation to Drive Globalization of New Drugs
This award is a strong affirmation of Honeybear’s progress in R&D, technology development, corporate governance, and international collaboration. It also reflects the high expectations from the industry regarding the potential of the CoNectar®/ARC platform.
Chairman Edward Wang commented that Honeybear Biosciences will continue to uphold its corporate values of innovation, integrity, and responsibility, seize global trends and opportunities in the biotech industry, and strive to transform its research achievements into new drugs that genuinely improve human health.
Looking forward, Honeybear is confident in stepping onto the global stage and authoring a new chapter in cancer treatment.
Sarina Lin, Vice Chairwoman of Honeybear Biosciences (Right) was representing the company
to accept the recognition of 24th “Business Startup Award”, the “Technology Industry” group,
from Minister Ming-Hsin Kung (Left), Ministry of Economic Affairs.
to accept the recognition of 24th “Business Startup Award”, the “Technology Industry” group,
from Minister Ming-Hsin Kung (Left), Ministry of Economic Affairs.
Vice Chairwoman Sarina Lin (Right) and CEO Simon Chuang (Left) attended the awarding ceremony of “24th Business Startup Award” together.
Innovation-focused team of Honeybear Biosciences
(Photo took at the Honeybear Biosciences office located in the NBRP)
(Photo took at the Honeybear Biosciences office located in the NBRP)
Please visit the news links for more related reports,
1、財訊https://www.wealth.com.tw/articles/ee90d404-a4a2-4c1b-b5a0-d960f557a612
2、經濟https://money.udn.com/money/story/5724/9153917
3、鉅亨網https://news.cnyes.com/news/id/6246197
4、Yam蕃新聞https://n.yam.com/Article/20251121573570
5、商傳媒https://pse.is/8d9lv6
6、獨家報導https://pse.is/8d9m3y
7、Life生活網https://life.tw/?app=view&no=2881577
8、警政時報https://www.tcpttw.com/other/other_industrial/2025/11/21/220041/
9、奧丁丁OwlNews https://news.owlting.com/articles/1192218
10、Line Today https://today.line.me/tw/v3/article/0MNojNG
11、理財周刊https://www.moneyweekly.com.tw/ArticleData/Info/Article/203490
12、民生電子報https://lifenews.com.tw/431976/
13、PChome新聞https://news.pchome.com.tw/finance/sunmedia/20251121/index-76369419982033329003.html
14、環球生技https://news.gbimonthly.com/tw/article/show.php?num=81889
15、樂聯網https://leho.com.tw/archives/215477
16、火報https://pse.is/8da9jp
1、財訊https://www.wealth.com.tw/articles/ee90d404-a4a2-4c1b-b5a0-d960f557a612
2、經濟https://money.udn.com/money/story/5724/9153917
3、鉅亨網https://news.cnyes.com/news/id/6246197
4、Yam蕃新聞https://n.yam.com/Article/20251121573570
5、商傳媒https://pse.is/8d9lv6
6、獨家報導https://pse.is/8d9m3y
7、Life生活網https://life.tw/?app=view&no=2881577
8、警政時報https://www.tcpttw.com/other/other_industrial/2025/11/21/220041/
9、奧丁丁OwlNews https://news.owlting.com/articles/1192218
10、Line Today https://today.line.me/tw/v3/article/0MNojNG
11、理財周刊https://www.moneyweekly.com.tw/ArticleData/Info/Article/203490
12、民生電子報https://lifenews.com.tw/431976/
13、PChome新聞https://news.pchome.com.tw/finance/sunmedia/20251121/index-76369419982033329003.html
14、環球生技https://news.gbimonthly.com/tw/article/show.php?num=81889
15、樂聯網https://leho.com.tw/archives/215477
16、火報https://pse.is/8da9jp
